Syndax announced SAVE data published in the *Journal of Clinical Oncology* on Revuforj® (revumenib) in combination with decitabine/cidazaril and venetoclax for the treatment of relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML. —GlobeNewswire

FDA Label Product: Revuforj. Active Ingredient/Generic Name: REVUMENIB. Company: Syndax Pharmaceuticals, Inc. Route of Administration: ORAL. Main Indications: 1. INDICATIONS AND USAGE: REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. (1) the t

Veneclare is a prescription drug that targets the BCL-2 protein. It was approved for marketing in the United States in April 2016. It should be used only as directed by a doctor.

Venetoclax is a world-first selective drug that targets the B-cell lymphoma-2 (BCL-2) protein. BCL-2 plays a crucial role in certain blood cancers or other cancers, preventing cancer cell death (apoptosis). Venetoclax works by blocking the BCL-2 protein, thus restoring the apoptosis process. Venetoclax aims to selectively inhibit BCL-2 function, restore cellular communication systems, and induce cancer cell self-destruction, thereby achieving the goal of treating tumors.